Santhera Pharmaceuticals Holding Ag Is A Swiss Specialty Pharmaceutical Company Based In Prattelnswitzerlandfounded In 2004The Company Focuses On Developing And Commercializing Innovative Treatments For Rare Neuromuscular And Pulmonary Diseasesparticularly Those With High Unmet Medical Needssuch As Duchenne Muscular Dystrophydmdand Cystic Fibrosis Santhera Operates Globallywith Products Approved In The Useuand Ukthe Company Employs A Licensing Strategypartnering With Catalyst Pharmaceuticals For The North American Market And Sperogenix Therapeutics For Chinaits Key Products Include Agamreevamorolone A First In Class Alternative To Traditional Corticosteroids For Dmdand Lonodelestata Clinical Stage Inhibitor Targeting Cystic Fibrosis And Other Neutrophilic Pulmonary Diseasessanthera Is Committed To Serving Patients With Rare Diseasesproviding Tailored Treatments For Both Pediatric And Adult Populations
